Astragalus injection is another commonly used Chinese patent medicine in the clinical treatment of chronic heart failure. Sixty-two randomized controlled trials (RCTS) and quasi-randomized controlled trials were reviewed. It was found that the quality of the test method was low, and the existing studies were not enough to prove the effectiveness and safety of Astragalus injection. The efficacy of hawthorn, cannabinoids and curcumin in the treatment of chronic heart failure has also been systematically evaluated.
Diao Xinxukang capsule has been approved by the State Food and Drug Administration and has been routinely used in China for several years. Its components are mainly extracted from the roots of Dioscorea zingiberensis. A randomized, multicentre, double-blind trial was conducted to evaluate its efficacy in angina pectoris compared with compound Danshen tablets. 733 patients were included in the analysis group. After 20 weeks of treatment, Xinxukang capsule successfully reduced the proportion of patients with angina. According to the score of Seattle Angina pectoris questionnaire and blood stasis syndrome score, Xinxukang can significantly improve the quality of life of patients. A review of randomized clinical trials on the efficacy of Xuenkang Capsule showed that Xuenkang capsule seemed to have better efficacy in patients with angina pectoris compared to isosorbide binitrate.
Xinmailong is another proprietary traditional Chinese medicine whose active ingredient is extracted from the American cockroach. Xinmaiolong has been shown to have a protective effect against ischemic myocardial injury. A systematic survey of 121 patients over a 15-day period explored the effects of Neomyron on patients with heart failure and compared its effects to standard treatment. In the standard treatment group, patients received regular prescriptions including digitalis preparations, beta-blockers, sodium nitroprusside, and aspirin. After 7 days of treatment with standard therapy and Xinmailong injection, cardiac function indicators, including high-sensitive C-reactive protein (hsCRP), NT_proBNP, LVEF and left ventricular end-systolic volume index returned to normal levels. Compared to the standard treatment, Simmalone performed better after 15 days of treatment. After 15 days of treatment, LVEF increased from 36.9% at the start of treatment to 46.4% (LVEF was 59.7% in the normal group). This cardioprotective effect of Xinmaiosaurus may be achieved by inhibiting angiotensin II and thus the renin-angiotensin-aldosterone system.